Studies of two Alzheimer’s drugs (bapineuzumab and solanezumab) ended in disappointment. The drugs are designed to fight the build up of an abnormal protein, beta-amyloid, in the brains of people with Alzheimer’s disease in order to delay or possibly even stop the progression of the illness. Intravenous versions of the drugs failed to help people with mild to moderate Alzheimer’s. But the preliminary evidence suggests that planned new clinical trials may produce better results.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.